Top

Published in:

Open Access 01-12-2008 | Short communication

A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice

Authors: Alice C Fan, Marianna M Goldrick, Jennifer Ho, Yu Liang, Pavan Bachireddy, Dean W Felsher

Published in: Molecular Cancer | Issue 1/2008

Abstract

MicroRNA (miRNA) dysregulation frequently occurs in cancer. Analysis of whole blood miRNA in tumor models has not been widely reported, but could potentially lead to novel assays for early detection and monitoring of cancer. To determine whether miRNAs associated with malignancy could be detected in the peripheral blood, we used real-time reverse transcriptase-PCR to determine miRNA profiles in whole blood obtained from transgenic mice with c-MYC-induced lymphoma, hepatocellular carcinoma and osteosarcoma. The PCR-based assays used in our studies require only 10 nanograms of total RNA, allowing serial mini-profiles (20 – 30 miRNAs) to be carried out on individual animals over time. Blood miRNAs were measured from mice at different stages of MYC-induced lymphomagenesis and regression. Unsupervised hierarchical clustering of the data identified specific miRNA expression profiles that correlated with tumor type and stage. The miRNAs found to be altered in the blood of mice with tumors frequently reverted to normal levels upon tumor regression. Our results suggest that specific changes in blood miRNA can be detected during tumorigenesis and tumor regression.

Available only for authorised users

Barbarotto E, Schmittgen TD, Calin GA: MicroRNAs and cancer: profile, profile, profile. International journal of cancer. 2008, 122 (5): 969-977. 10.1002/ijc.23343.CrossRef

Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences USA. 2002, 99 (24): 15524-15529. 10.1073/pnas.242606799.CrossRef

Croce CM, Calin GA: miRNAs, cancer, and stem cell division. Cell. 2005, 122 (1): 6-7. 10.1016/j.cell.2005.06.036CrossRefPubMed

, : MicroRNAs and cancer: Profile, profile, profile. International Journal of Cancer. 2008, 122 (5): 969-977. 10.1002/ijc.23343.

Esquela-Kerscher A, Slack FJ: Oncomirs [mdash] microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6 (4): 259-269. 10.1038/nrc1840CrossRefPubMed

Gaur AB, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VA, Israel MA: Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67(6):2456-68. 2007, 67 (6): 2456-2468. 10.1158/0008-5472.CAN-06-2698.CrossRef

He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu C-g, Franssila K, Suster S: The role of microRNA genes in papillary thyroid carcinoma. Proceedings of the National Academy of Sciences. 2005, 102 (52): 19075-19080. 10.1073/pnas.0509603102.CrossRef

Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD: Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival. Clin Cancer Res. 2008, 14 (2): 419-427. 10.1158/1078-0432.CCR-07-0523PubMedCentralCrossRefPubMed

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA: MicroRNA expression profiles classify human cancers. Nature. 2005, 435 (7043): 834-838. 10.1038/nature03702CrossRefPubMed

10.

Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M: A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences. 2006, 103 (7): 2257-2261. 10.1073/pnas.0510565103.CrossRef

11.

Croce CM: Oncogenes and cancer. New England Journal of Medicine, The. 2008, 358 (5): 502-511. 10.1056/NEJMra072367.CrossRef

12.

Chang T-C, Yu D, Lee Y-S, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT: Widespread microRNA repression by Myc contributes to tumorigenesis. Nature genetics. 2008, 40 (1): 43-50. 10.1038/ng.2007.30PubMedCentralCrossRefPubMed

13.

Chen CZ: MicroRNAs as oncogenes and tumor suppressors. New England Journal of Medicine. 2005, 353 (17): 1768-1771. 10.1056/NEJMp058190CrossRefPubMed

14.

Cho WCS: OncomiRs: the discovery and progress of microRNAs in cancers. Molecular cancer. 2007, 6: 60-60. 10.1186/1476-4598-6-60PubMedCentralCrossRefPubMed

15.

He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ: A microRNA polycistron as a potential human oncogene. Nature. 2005, 435 (7043): 828-833. 10.1038/nature03552CrossRefPubMed

16.

Lawrie CH: MicroRNA expression in lymphoma. Expert Opinion on Biological Therapy. 2007, 7 (9): 1363-1374. 10.1517/14712598.7.9.1363CrossRefPubMed

17.

Lawrie DW, Gal DW, Dunlop DW, Pushkaran DW, Liggins DW, Pulford DW, Banham DW, Pezzella DW, Boultwood DW, Wainscoat DW: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008, 141 (5): 672-675. 10.1111/j.1365-2141.2008.07077.xCrossRefPubMed

18.

Rai D, Karanti S, Jung I, Dahia PLM, Aguiar RCT: Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genetics and Cytogenetics. 2008, 181 (1): 8-15. 10.1016/j.cancergencyto.2007.10.008.PubMedCentralCrossRefPubMed

19.

Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A: MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated With Distinctive Pathologic Features and Clinical Behavior. J Clin Oncol. 2006.

20.

Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Krueger LJ: MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer research. 2007, 67 (20): 9762-9770. 10.1158/0008-5472.CAN-07-2462CrossRefPubMed

21.

Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, Hersch SM, Hogarth P, Bouzou B, Jensen RV: Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proceedings of the National Academy of Sciences. 2005, 102 (31): 11023-11028. 10.1073/pnas.0504921102.CrossRef

22.

Burczynski ME, Dorner AJ: Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics. 2006, 7 (2): 187-202. 10.2217/14622416.7.2.187CrossRefPubMed

23.

Burczynski ME, Peterson RL, Twine NC, Zuberek KA, Brodeur BJ, Casciotti L, Maganti V, Reddy PS, Strahs A, Immermann F: Molecular Classification of Crohn's Disease and Ulcerative Colitis Patients Using Transcriptional Profiles in Peripheral Blood Mononuclear Cells. J Mol Diagn. 2006, 8 (1): 51-61. 10.2353/jmoldx.2006.050079PubMedCentralCrossRefPubMed

24.

Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, Stadler WM, Logan T, Dutcher J, Hudes G, Trepicchio WL: Transcriptional Profiles in Peripheral Blood Mononuclear Cells Prognostic of Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma. Clin Cancer Res. 2005, 11 (3): 1181-1189.PubMed

25.

Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P: Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005, 309 (5740): 1577-1581. 10.1126/science.1113329CrossRefPubMed

26.

Sharp FR, Xu H, Lit L, Walker W, Apperson M, Gilbert DL, Glauser TA, Wong B, Hershey A, Liu D-Z: The Future of Genomic Profiling of Neurological Diseases Using Blood. Arch Neurol. 2006, 63 (11): 1529-1536. 10.1001/archneur.63.11.1529CrossRefPubMed

27.

Tang Y, Gilbert DL, Glauser TA, Hershey AD, Sharp FR: Blood Gene Expression Profiling of Neurologic Diseases: A Pilot Microarray Study. Arch Neurol. 2005, 62 (2): 210-215. 10.1001/archneur.62.2.210CrossRefPubMed

28.

Tang Y, Lu A, Ran R, Aronow BJ, Schorry EK, Hopkin RJ, Gilbert DL, Glauser TA, Hershey AD, Richtand NW: Human blood genomics: distinct profiles for gender, age and neurofibromatosis type 1. Molecular Brain Research. 2004, 132 (2): 155-167. 10.1016/j.molbrainres.2003.10.014CrossRefPubMed

29.

Tang Y, Nee AC, Lu A, Ran R, Sharp FR: Blood genomic expression profile for neuronal injury. J Cereb Blood Flow Metab. 2003, 23 (3): 310-319. 10.1097/00004647-200303000-00006CrossRefPubMed

30.

Tang Y, Schapiro MB, Franz DN, Patterson BJ, Hickey FJ, Schorry EK, Hopkin RJ, Wylie M, Narayan T, Glauser TA: Blood expression profiles for tuberous sclerosis complex 2, neurofibromatosis type 1, and Down's syndrome. Annals of neurology. 2004, 56 (6): 808-814. 10.1002/ana.20291CrossRefPubMed

31.

Felsher DW, Bishop JM: Reversible tumorigenesis by MYC in hematopoietic lineages. Molecular cell. 1999, 4 (2): 199-207. 10.1016/S1097-2765(00)80367-6CrossRefPubMed

32.

Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002, 297 (5578): 102-104. 10.1126/science.1071489CrossRefPubMed

33.

Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, Bradon N, Arvanitis C, Attardi LD, Feng S, Ruebner B: Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol. 2004, 2 (11): e332- 10.1371/journal.pbio.0020332PubMedCentralCrossRefPubMed

34.

Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004, 431 (7012): 1112-1117. 10.1038/nature03043CrossRefPubMed

35.

Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegue E, Tang F: Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci USA. 2006, 103 (44): 16266-16271. 10.1073/pnas.0608017103PubMedCentralCrossRefPubMed

36.

Wu C-H, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW: Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proceedings of the National Academy of Sciences of the United States of America. 2007, 104 (32): 13028-13033. 10.1073/pnas.0701953104PubMedCentralCrossRefPubMed

37.

Tran TP, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, Horng G, Bellovin DI, Giuriato S, Wang CS: Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PloS one. 2008, 3 (5): e2125- 10.1371/journal.pone.0002125PubMedCentralCrossRefPubMed

38.

Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K: Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nature immunology. 2008, 9 (4): 405-414. 10.1038/ni1575PubMedCentralCrossRefPubMed

39.

Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T: Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Science. 2007, 98 (12): 1914-1920. 10.1111/j.1349-7006.2007.00618.xCrossRefPubMed

40.

Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW: Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci USA. 2003, 100 (17): 9974-9979. 10.1073/pnas.1732638100PubMedCentralCrossRefPubMed

41.

Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW: Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood. 2003, 101 (7): 2797-2803. 10.1182/blood-2002-10-3091CrossRefPubMed

42.

Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J, Mitchell DJ: Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood. 2007, 110 (7): 2674-2684. 10.1182/blood-2006-09-048033PubMedCentralCrossRefPubMed

43.

Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, Bujard H: Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA. 1996, 93 (20): 10933-10938. 10.1073/pnas.93.20.10933PubMedCentralCrossRefPubMed

Title: A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice
Authors: Alice C Fan
Marianna M Goldrick
Jennifer Ho
Yu Liang
Pavan Bachireddy
Dean W Felsher
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2008
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-7-74

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Insulin-like growth factor-I gene therapy reverses morphologic changes and reduces hyperprolactinemia in experimental rat prolactinomas

Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity

Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers

Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties?

Gene expression profiles in primary pancreatic tumors and metastatic lesions of Ela-c-myc transgenic mice

DNA-dependent protein kinase catalytic subunit modulates the stability of c-Myc oncoprotein

Keynote webinar | Spotlight on antibody–drug conjugates in cancer